Press Release FeedGet the RSS feed
Menu

GlobeNewswire

European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapse

Johnson & Johnson

BEERSE, BELGIUM, Oct. 23, 2026 -- Johnson & Johnson, a worldwide leader in multiple myeloma, today announced that the European Commission (EC) has approved an indication extension of TECVAYLI® (teclistamab) for the treatment of adult patients with relapsed/refractory multiple myeloma (RRMM) who have received at least one prior therapy. Building on the recent EC approval of teclistamab plus daratumumab, this indication extension introduces teclistamab monotherapy as an additional second-line treatment option for patients living with RRMM and reinforces the wider potential of teclistamab across both monotherapy and combination approaches for patients at first relapse.1,2

  1. AIGlobal Life Science Market Report 2026: Size, Trends and Forecast to 2030 | Secure $200.6B AI and Precision Medicine Upside with Johnson & Johnson, Roche, Pfizer, and AstraZenecaCompanies: Johnson & JohnsonAstraZenecaPfizerRoche Holding"Life Science Market Report 2026" has been added to ResearchAndMarkets.com's offering.
  2. 小売特化ハイブリッドクラウドPOSレジ「poscm_plus」がリファンド方式に対応！株式会社 J&J Tax Free社と連携が可能にCompanies: Johnson & Johnson[株式会社ウェブベース] 株式会社ウェブベース（本社：大阪府豊中市、代表取締役社長 兼 CEO：野口 聡之 、以下「当社」）が提供する小売特化ハイブリッドクラウドPOSレジ「poscm_plus（ポスカムプラス）」（以下、poscm_plus）は、株式...
  3. SaaSJohnson & Johnson to Showcase the Future of Surgical Intelligence at Abu Dhabi Future Health Summit 2026Companies: Johnson & JohnsonCompany to showcase MONARCH™ robotics platform and Polyphonic™ digital ecosystem New ecosystem collaboration announced at the event will support the future of surgical intelligence ABU DHABI, United Arab Emirates, October 20, 2026--Johnson & Johnson will showcase digital surgery technologies and its st
  4. Una nuova analisi basata su modelli conferma ulteriormente il potenziale di TECVAYLI®▼ (teclistamab) in associazione con daratumumab nel ridefinire le aspettative di sopravvivenza a lungo termine nel mieloma multiplo recidivante/refrattario trattato in prima lineaCompanies: Johnson & JohnsonJohnson & Johnson, leader mondiale nel campo del trattamento del mieloma multiplo, ha annunciato oggi nuovi dati provenienti dallo studio di Fase 3 MajesTEC-3, che dimostrano un controllo della malattia e una sopravvivenza duraturi con TECVAYLI® (teclistamab) in associazione con daratumumab nei pazienti affetti da mieloma multiplo recidivante o refrattario (RRMM) che avevano precedentemente ricevuto da 1 a 3 linee di terapia.
  5. Eine neue modellbasierte Analyse untermauert das Potenzial von TECVAYLI®▼ (teclistamab) in Kombination mit daratumumab, die Erwartungen hinsichtlich des Langzeitüberlebens bei einem rezidivierten bzw. refraktären multiplen Myelom in frühen Behandlungslinien neu zu definierenCompanies: Johnson & JohnsonJohnson & Johnson, ein weltweit führendes Unternehmen im Bereich des multiplen Myeloms, gab heute neue Daten aus der Phase III-Studie MajesTEC-3 bekannt, die eine anhaltende Krankheitskontrolle und Überlebenszeit unter TECVAYLI® (teclistamab) in Kombination mit daratumumab bei Patienten mit rezidiviertem oder refraktärem multiplem Myelom (RRMM) belegen, die zuvor 1 bis 3 Therapielinien erhalten hatten.
  6. Une nouvelle analyse modélisée renforce le potentiel de TECVAYLI®▼ (teclistamab) associé au daratumumab pour redéfinir les perspectives de survie à long terme dans le myélome multiple en rechute/réfractaire dans les premières lignes de traitementCompanies: Johnson & JohnsonBEERSE, Belgique, 28 sept. 2026 -- Johnson & Johnson, leader mondial dans le domaine du myélome multiple, a annoncé aujourd’hui de nouvelles données issues de l’étude de Phase 3 MajesTEC-3, mettant en évidence un contrôle durable de la maladie et une survie prolongée avec TECVAYLI® (teclistamab) associé au daratumumab chez des patients atteints d’un myélome multiple en rechute ou réfractaire (MMRR) ayant reçu 1 à 3 lignes de traitement antérieures.